Procore signs multi-year strategic collaboration agreement with AWS
NEWPORT BEACH, CA—Evolus, Inc. (NASDAQ:EOLS) Chief Medical (TASE:PMCN) Officer and Head of Research and Development, Rui Avelar, has recently sold 2,252 shares of the company's common stock. The transaction, which took place on December 23, was executed at an average price of $10.85 per share, resulting in a total value of approximately $24,438. The stock, which has since risen to $11.35, appears undervalued according to InvestingPro analysis, with revenue growing at an impressive 34% year-over-year.
According to the filing, the sale was conducted under a Rule 10b5-1 trading plan and was necessary to cover tax withholding obligations related to the vesting of restricted stock units. Following this transaction, Avelar retains ownership of 366,595 shares in Evolus. InvestingPro data shows the company maintains strong liquidity with a current ratio of 2.47, while offering additional insights through its comprehensive Pro Research Report covering 1,400+ US stocks.
In other recent news, Evolus, Inc. held its third quarter 2024 earnings conference call, revealing the company's financial results and operational progress. Led by Vice President and Head of Global Investor Relations Nareg Sagherian, the call featured insights from President and CEO David Moatazedi, Chief Medical Officer Rui Avelar, and CFO Sandra Beaver. Evolus discussed its current financial position, presenting both non-GAAP financial measures and GAAP results, with a reconciliation provided in the publicly available earnings release. The company also discussed forward-looking statements, cautioning that actual results could differ due to various risks and uncertainties. These recent developments reflect Evolus' ongoing commitment to transparency and communication with its investors. The detailed financial data and reconciliations of non-GAAP measures are available on Evolus' official website and through the SEC's filing system.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.